What is RSV and why are infants especially at risk in India?
Respiratory Syncytial Virus, commonly known as RSV, is the leading cause of respiratory illness in children and infants worldwide. In India, RSV has also become a major issue for parents as well as pediatricians, particularly in the post-monsoon and winter seasons when cases surge.
Although the nation continues to establish complete surveillance information, existing studies in tertiary care facilities show that RSV contributes 30% to 50% of bronchiolitis and pneumonia incidents in children aged two years and below.
RSV is usually responsible for the symptoms of a cold in older children and adults. Nevertheless, in infants—especially those under six months of age, those who were premature at birth, or those with underlying health issues—the virus may cause severe lower respiratory tract infections, including bronchiolitis (inflammation of small airways) and pneumonia.
These two diseases usually require hospitalization, and hospitalization rates between 3 and 5 per 100 infants less than one year of age per year have been estimated in India.
The risks are not equal throughout the nation. Geographic and socioeconomic variations account for both the risk of and outcome of RSV infection. Children living in lower-income populations or in densely populated urban environments can have increased exposure from lesser access to healthcare, suboptimal ventilation, and slower diagnosis.
by Taboola
by Taboola
Sponsored Links
Sponsored Links
Promoted Links
Promoted Links
You May Like
Eat 1 Teaspoon Every Night, See What Happens A Week Later [Video]
getfittoday
Undo
Seeing the international burden of RSV, the World Health Organization (WHO) recently supported maternal RSV vaccination as a prevention approach. This entails immunizing pregnant women so that antibodies are passed on to the unborn child, providing immunity in the vulnerable early months of life. Although not yet included in India's Universal Immunization Programme (UIP), Indian health authorities, such as the Indian Academy of Pediatrics, are in the process of evaluating the vaccine's safety, effectiveness, and affordability in India.
Phased introduction in high-risk groups could be the initial step.
Apart from vaccines, monoclonal antibodies too have been promising in the prevention of RSV-related complications. These provide passive immunity in a single dose of injection. But the big constraint is cost. Without government incentives or being covered under public health schemes, these therapies could prove to be out of reach for the majority of Indian families.
Differential pricing models and collaborations with insurance companies will become paramount in order to expand access.
More encouragingly, Indian drug makers are not idle either. Bharat Biotech and Serum Institute of India have initiated RSV research programs and are likely to bank on their experience in the production of pediatric and maternal vaccines. Tie-ups with global firms can also open the way for local production of monoclonal antibodies, leading to costs savings as well as wider availability.
Experts put wide availability of RSV vaccines and antibodies in India at least 2 to 4 years down the road. Early access could start in corporate or private hospitals dealing with high-risk pregnancies. In the private sector, however, the incorporation of RSV prevention in the national immunization program will be crucial to making RSV vaccines and antibodies accessible and beneficial for all Indian infants—irrespective of birthplace.
Article courtesy: Dr. Shreya Dubey - Consultant - Neonatology & Paediatrics, CK Birla Hospital, Gurugram
Russia's Lavrov Sounds Alarm Over German Army Buildup Plan; 'Very Worrying, Need To…'
One step to a healthier you—join Times Health+ Yoga and feel the change
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Time of India
29 minutes ago
- Time of India
Megalithic era pottery unearthed at village farm in Haveri
Haveri: A research team led by MR Shadaksharayya, a former professor from Karnatak University's history and archaeological department in Dharwad, unearthed Megalithic artefacts in Balambeed village, Hirekerur taluk, Haveri district. The discoveries, found on Mallikarjun Jogihalli's land, include 3000 BC pottery fragments and ancient materials merely six inches beneath the surface. Some findings suggest links to the Palaeolithic era. The research group, comprising historians Iranna Pattar, Nagarajappa MS, and MM Akki, located this archaeological site and gathered historical evidence from the agricultural land. Their findings include fossils of black-and-red pottery, characteristic of the Palaeolithic and Megalithic periods. The pottery collection features carinated vessels, pedestal bowls, spouted dishes, and distinctive conical lids with top loops. The Indian Megalithic culture primarily corresponds to the Iron Age (1500 BC–500 BC), with some sites showing Chalcolithic-Megalithic characteristics. The Palaeolithic period dates to 3000 BC. Previous archaeological discoveries in Karnataka include sites at Maski, Hallur, Chandravalli, Hire Benkal, Coorg, Heggadehalli, and Brahmagiri. by Taboola by Taboola Sponsored Links Sponsored Links Promoted Links Promoted Links You May Like Giao dịch CFD với công nghệ và tốc độ tốt hơn IC Markets Đăng ký Undo The Balambeed village site offers fresh insights into the district's historical development. "The owner of the land came upon pottery while they were digging at least 18 inches. Not only this, many different types of pottery pieces were found in different spots at the farmland, and these are like those we found earlier in Hallur in Hirekerur taluk, Maski, Yallur village in Harapanahalli taluk. Some bone pieces were also found at the same spot," informed Prof Shadaksharayya. He indicated that these shallow-depth discoveries suggest the presence of substantial Stone Age burial grounds. Initial evidence points towards significant historical value requiring additional research. Former Archaeological Survey of India authority Narashimhaiah previously identified Stone Age implements in the region. "Villages were common among the Megalithic people. Megalithic people cultivated rice, wheat, ragi, and domesticated animals like donkeys and buffalo. Different types of pottery, including high-quality red and black pottery, are associated with the Megalithic culture, so these fossils are better leads to further studies," Shadaksharayya stated. "We preserved the fossils that were found in the farmland. We also requested the landowner not to harm such ancient pieces because they are valuable for study, and they also agreed to this," shared MM Akki, another member of this team. Caption: Ancient pottery and other stone materials belonging to the Palaeolithic and Megalithic era were discovered in the Balambeed village of Hirekerur taluk of Haveri district recently
Time of India
30 minutes ago
- Time of India
One cough too many: India's TB fight isn't quite there yet
Tired of too many ads? Remove Ads Tired of too many ads? Remove Ads MISSING CASES Tired of too many ads? Remove Ads NEW HOPE, OLD GAPS A CURE WITH ISSUES WHAT NEXT? One moment Anushka (name changed) was a college student. Then her world turned upside down. It started with a persistent cough and high fever. Despite popping meds, it wouldn't go away. Tests followed and then came the news that knocked the stuffing out of her—she had a fatal form of tuberculosis TB ). With scarred lungs, she gasped for each breath. The bacteria had killed her appetite, making her frail and bony. Her skin colour changed—to dark and then grew paler. At 20, her life expectancy dwindled to a few months.'I felt weak,' she recalls, 'and preferred to be alone.'Battling extensively drug-resistant tuberculosis or XDR-TB, a form of the disease in which drugs rarely worked, Anushka's only option was to be loaded each day with scores of tablets and injections. Those came with toxic side effects. For over four years, she moved between government and private hospitals, enduring cycles of failed came only when she was placed on a salvage regimen—the last option when all other interventions are exhausted—at a Médecins Sans Frontières (MSF) clinic in Govandi, Mumbai. The global humanitarian group offered Anushka a cocktail of bedaquiline , delamanid and imipenem injections, a set of very powerful meds often inaccessible to most Indians due to supply restrictions aimed at curbing drug who has now recovered, recounted her ordeal at MSF's TB Day event in Mumbai on May 12, speaking before an audience of doctors, a quiet smile breaking through years of pain. Her journey to recovery is rare, and alien to millions in India, which reflects a public health system still failing its most vulnerable. India now accounts for more than a quarter of all TB cases reported worldwide. In 2023, the country had 26% of the global TB burden, according to the World Health Organization (WHO). Bending the curve remains difficult despite multiple national can India improve?In 2018, when India pledged to eliminate TB by 2025, five years ahead of the set global target, the objective was clear. And progress has been made, too. Between 2015 and 2023, TB incidence (new and relapsed cases per 1 lakh population every year) fell by 18% and deaths by 24%, per is a sign in the right direction, but the number of cases are still astounding, especially when it comes to drug-resistant variants. 'India bears the highest burden of XDR-TB globally, with an estimated 110,000 new cases annually,' says Professor Anil Koul of the London School of Hygiene and Tropical Medicine. A key figure in TB drug research, Koul was part of a Johnson & Johnson team that developed bedaquiline, one of the most effective drugs against resistant TB notes that Covid-19 deepened the crisis, and underfunded research has stalled progress. Of the 27 drugs in clinical trials, none have reached Phase III. Bedaquiline remains the mainstay.A 100-day TB Elimination Challenge was launched by the government in December 2024 to amplify efforts to diagnose and treat TB at the village level, but experts aren't satisfied.'We are not on track,' says Dr Animesh Sinha, chronic care and infectious disease advisor, MSF. 'To meet the 2025 milestones of WHO's End TB strategy, India should achieve a 50% reduction in TB incidence rate and a 75% reduction in the total number of TB deaths compared with 2015.' Although numbers have fallen, the quantum has been woefully short of the target, as WHO numbers suggest.A PIB release dated March 24, 2025, says India's TB elimination targets for 2025 are an 80% reduction in incidence and a 90% reduction in deaths, compared with 2015.A key problem is underreporting emanating from under-diagnosis. India's notification rate (number of TB cases diagnosed and officially reported) has improved from 108 per 100,000 population in 2010 to 166 in 2023, yet many cases, especially in rural areas, go undetected.'In order to address the TB crisis, we have to find the missing cases,' says Sinha. Nonetheless, the 2025 goal helped push TB up the political agenda. Ni-kshay, a digital platform for notification and treatment monitoring, is improving reporting. But without proportionate investment in diagnostics, staffing and drug access, the pace of progress will be drug shortages have been reported, and India spent just 2.1% of the National Tuberculosis Elimination Programme budget on diagnostics till 2023-24, an IndiaSpend RTI revealed.'The 2025 target was always a stretch,' says Koul. 'But it did galvanise government machinery, leading to faster approvals for newer regimens like bedaquiline, speedier rollout across TB centres and more budgetary support, including for nutritional aid.'That said, TB continues to receive only a sliver of public health funding. But even so, he notes, there certainly is a positive trend in fighting back, considering the complexity of the disease and the socioeconomic factors shaping in an ET Morning Brief podcast in January, Dr Urvashi Singh, deputy director-general (TB), Ministry of Health and Family Welfare, said, 'The domestic budget for the national TB programme has increased over five times in the last 10 years.' India, she added, is the only high-burden country where 91% of the programme is backed by domestic detection is often the difference between quick recovery and years of suffering. Goa-based diagnostic device maker Molbio Diagnostics' Truenat, a portable molecular-testing platform, introduced in 2017, expanded diagnostic access, particularly in low-access regions. 'We supplied over 90 lakh testing kits last year and expect to provide 1.25 crore this year,' says Sriram Natarajan, CEO of Molbio, which is working with government and statelevel partners to rollout molecular testing.A Truenat test costs just Rs 640, a fraction of what imported diagnostics demand, says Natarajan. In public health, he argues, the real measure isn't price, but cost-effectiveness, especially when early detection can avert far greater globally approved diagnostics protocols remain out of reach in India. The WHO-recommended urine TBLAM test, used to diagnose TB in HIVpositive patients, is still unavailable in the country, despite successful validation studies in Mumbai in 2022. Registration barriers and lack of supply from manufacturers have led to lack of access, says Leena Menghaney, a public health lawyer based in Delhi. Supplyrelated issues could be because trials in India have yet to conclude, according to industry delays cost precious lives. Late detection risks high transmission rates and complications for patients. Dr Jennifer Furin, infectious diseases clinician, Harvard Medical School, says while Truenat is helpful and the diagnostic pipeline is robust, the outdated and slow systems for approving novel tools in India have a detrimental impact. Furin points to a critical gap: the lack of household-level prevention. Studies, including a 2023 trial published in TheLancet, show that modest nutritional support for families of TB patients can sharply reduce transmission. Another model, published in TheLancet this year, estimates that improving household nutrition alone could prevent nearly 5% of TB deaths by carrying the world's highest TB burden, regulatory reforms have been slow in India. Some gains have been made, but systemic delays continue to blunt the impact of new patients with drug-resistant TB, a new wave of treatment offers hope, but conditions apply. Regimens like a six-month, all-oral combination termed BPaLM— bedaquiline, pretomanid, linezolid and moxifloxacin—have been game-changers, replacing the gruelling 24-month regimens of daily injections and pills. 'These regimens are better tolerated and highly effective, with about 90% of people completing treatment successfully,' says clinicians welcome the government's push for shorter regimens, access remains limited—only 1,700 patients in India have received them, according to Dr Rupak Singla, head of the department of respiratory medicine, National Institute of Tuberculosis and Respiratory Diseases , Delhi, who spoke at the event in Mumbai. Adoption has lagged due to limited access to drug susceptibility testing for newer drugs, which is crucial for choosing an appropriate treatment BPaLM regimen can't be given in cases where more than one organ system is involved or in patients with severe extrapulmonary disease, 'both of which are common in India,' according to Dr Alpa Dalal, head of unit, Group of TB Hospitals, Sewri, Mumbai. BPaLM should not be prescribed for patients previously treated with bedaquiline, says Dalal, unless drug susceptibility to bedaquiline and linezolid is says even in extensive pulmonary TB, where studies have shown good outcomes with BPaLM, many clinicians are cautious. In longer regimens, patients with extensive lung involvement have had higher relapse rates, compared with patients with limited disease, she explains, and that concern carries over. A study published in OUP's research platform, Oxford Academic, in March 2025 shows that bedaquiline resistance among previously treated patients can reduce the drug's warn that such resistance could undercut its effectiveness in the long term if not addressed early. But Koul says, 'Bedaquiline has galvanised TB R&D. It will remain a core component of future regimens, unless we see a dramatic rise in resistance in clinical practice.'The economics of care create barriers too. Pricing is a big hurdle. Regimens with imipenem cost thousands of rupees per day. Anushka was treated free by MSF. Else each injection alone, she said, would cost Rs 2,499. Considering the socioeconomic realities of India, perhaps this is where the government could step approach to procurement is problematic too. The country selectively joins pooled procurement platforms like the Global Drug Facility, which could reduce costs. 'India has in the past refused to participate in this, unless they had an emergency,' says policy and procurement, TB is a profoundly social disease, shaped by stigma, poverty and undernutrition. Even the best drugs won't work if care doesn't reach those who need it most. Guidelines may improve and approvals may accelerate but until the system meets people where they are, too many will be left suffered for years before she got cured. Her strength wasn't just in surviving; it was in refusing to give up. 'Even in that condition, I completed my graduation and kept chasing my dreams,' she says. India's TB response must now rise to match that grit, with urgency, equity and compassion.
The Hindu
an hour ago
- The Hindu
IIT-Kgp app helps commuters pick ‘greener' routes on the road
Bengaluru: Ambient air pollution is responsible for 7.2% of deaths in major Indian cities every year. There's reason to believe airborne particulate matter can cut the life expectancy of Indians by up to five years. But traffic-related pollution is usually much worse than what urban sensors report. Researchers have estimated commuting takes up only around 8% of a person's day but accounts for 33% of their pollution exposure. IIT Kharagpur associate professor Arkopal Kishore Goswami, his PhD student Kapil Kumar Meena, and intern Aditya Kumar Singh (from IIITM Gwalior) found that while traffic significantly affects commuters' health, few were aware of its actual risks. Realising access to information was key, the team created the Dynamic Route Planning for Urban Green Mobility (or DRUM) web app. It's like Google Maps but with the added feature of allowing users pick routes based on air quality and energy efficiency. Cleaner commute DRUM gives users five route options: shortest, fastest, least exposure to air pollution (LEAP), least energy consumption route (LECR), and a combination of all four factors called the suggested route. These options are based on real-time air and traffic data. When applied to Delhi, the LEAP route reduced exposure by over 50% in Central Delhi while increasing commute time by 40%. LECR meanwhile helped reduce energy consumption by 28% in South Delhi. These tradeoffs may not work for everyone, especially given the added fuel costs of longer routes, but DRUM could make a difference for more vulnerable groups, Mr. Meena said. Behind the build Integrating real-time air and traffic data was the project's biggest technical challenge, per Mr. Meena. The team's first obstacle was sparse data collection. According to UrbanEmissions, India needs around 4,000 continuous air quality stations. But by late 2024 the Central Pollution Control Board (CPCB) operated only 1,385, Mr. Meena said. This shortfall is particularly stark in megacities like Delhi. Its 40 monitoring stations leave many areas in a blindspot. Instead, the team relied on data from the CPCB and the World Air Quality Index. They implemented a segment-wise interpolation strategy to estimate pollution levels in areas without direct sensor coverage, divided routes into segments, and used nearby sensor data to estimate pollution where coverage was missing. To achieve higher responsiveness, DRUM was designed to fetch live pollution and traffic data the moment a user entered a route instead of pulling data at intervals. The backend was optimised for speed while the frontend offered a clean interface. DRUM determines routes using GraphHopper, a Java-based routing library that generates multiple options, while fetching real-time traffic updates from Mapbox. This setup allows the system to handle different vehicles and adapt to cities beyond Delhi. How it works At the heart of DRUM is a rank-based elimination method. 'The logic is deliberately practical: we prioritise time first because exposure is a function of concentration times time — the longer you're exposed, the more pollutants you inhale.' Next comes distance, since shorter routes have lower emissions and fuel use even if the travel time is similar. 'After that,' Mr. Meena continued, 'we eliminate routes with higher pollution exposure, and finally, those with higher energy consumption, which we calculate based on elevation and average speed. The final output is a single suggested route that balances all four factors.' To test the system, the team simulated Delhi's East, South, North, and Central corridors, accounting for different traffic, road quality, and pollution patterns. The results showed that shorter or faster routes often passed through polluted zones, offsetting time or distance gains. What next? DRUM has shown promise in simulations and Prof Goswami's MUST Lab at IIT-Kharagpur now plans real-world tests. They're also exploring integrating crowdsourced data with data from low-cost sensors on vehicles, street poles or even those carried by commuters. 'A major advantage of crowdsourced data is that it would allow us to expand the model beyond cars and two-wheelers, which are currently the only modes included,' Mr. Meena said. 'With user-contributed data from cyclists or pedestrians … we could incorporate micro-mobility modes.' The team is also looking to DRUM 2.0, a predictive version that responds to current data as well as forecasts future air quality, traffic, and energy use. Using machine learning models such as LSTM or Prophet, it could suggest the best route now and the best time to leave. This shift would make DRUM a truly smart mobility assistant, tailored for daily life in India's most polluted cities. Ashmita Gupta is a science writer.
